← OTLK

Session Pulse

Pre-market

2 mentions in the stream.

The Tape

$1.07

-24.20% last regular session

Filings

No SEC filings since the last regular close. The record is quiet.

Headlines

Outlook Therapeutics Announces LYTENAVA™ FDA Approval as the First and Only FDA-Approved Ophthalmic Bevacizumab for the Treatment of Wet AMD GlobeNewswire Inc. · Jul 24, 2:40 PM ET

Social

TAGGED OPINIONS

1 of 1 sentiment tags ran bullish across 2 mentions

No social mentions in the current stream.

Every item above links to its source · Historical record, not a forecast · The wolf reports; you decide